a post hoc analysis of SELECT|PsA 1 and 2 trials

Persistent Patient‐Level Effect of Guselkumab at Consecutive 8 ...

As such, post hoc analyses of the 2-year DISCOVER-2 trial of biologic-naïve patients with active PsA were conducted to evaluate individual ...

SKYRIZI® Efficacy in Active Psoriatic Arthritis (PsA)

Effects of treatment with risankizumab on reducing pain and inflammation in patients with psoriatic arthritis: an analysis of the KEEPsAKE-1 and -2 trials.

Psoriatic Arthritis Data from the PALACE 1-3 Study for the Treatment ...

The post-hoc analyses included patients from the PALACE 1, 2, 3, and 4 clinical trials receiving Otezla 30 mg BID who had undergone randomization at baseline ...

Guselkumab Delivers Long-Term PsA Improvements Among ...

... PsA symptoms and quality of life. Researchers conducted a post-hoc analysis utilizing data from the DISCOVER-2 trial (ClinicalTrials.gov ...

ACR_Journals on X: "Post hoc analysis of 104-week data from the ...

Post hoc analysis of 104-week data from the SELECT-PsA 1 and 2 trials found patients with psoriatic arthritis who achieved responses in ...

SELECT-PsA 1 & SELECT-PsA 2: Oral Targeted Therapy for PsA ...

Treat-To-Target: Low Disease Activity. In another combined post-hoc analysis of SELECT-PsA 1 and SELECT-PsA 2 (Mease P et al. ACR Convergence ...

Active Psoriatic Arthritis (PsA) Treatment | TREMFYA® (guselkumab ...

Open-label active treatment NRI post hoc analysis at Week 100. No ... The primary endpoint, ACR20 at Week 24, was met in the TREMFYA ® arms in 2 clinical trials.

Guselkumab provides durable improvement across psoriatic arthritis ...

Methods Post hoc analyses used data from DISCOVER-2 (NCT03158285) biologic/Janus-kinase inhibitor-naïve participants with active PsA (≥5 swollen/≥5 tender ...

"Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis ...

... analysis evaluated the efficacy and safety of guselkumab in patients with PsA in Russia. METHODS: This post hoc analysis of DISCOVER-1 and -2 ...

Multiple Endpoints in Clinical Trials Guidance for Industry | FDA

Although post hoc analyses of trials that fail on their. 303 prospectively ... 1/2, the first test for the truncated Holm test. 1443 is performed at α1 ...

Upadacitinib (RINVOQ) in Psoriatic Arthritis National Drug ... - VA.gov

Ongoing extension studies of up to 5 years' duration are ongoing. SELECT-PsA 1 and SELECT-PsA 2 Trials ... post-hoc analyses of psoriatic arthritis-related ' ...

Disease Control with Upadacitinib in Patients with Psoriatic Arthritis

... a post hoc analysis of the double-blind, placebo-controlled SELECT-PsA 1 (also adalimumab-controlled) and SELECT-PsA 2 trials. Treatment targets assessed ...

Long-term safety of Ixekizumab in adults with psoriasis, psoriatic ...

... a post-hoc analysis of final safety data from 25 randomized clinical trials. ... 1 to > = 2). IRs per 100 PY of discontinuation from IXE ...

Disease Control with Upadacitinib in Patients with Psoriatic Arthritis

Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis ... SELECT-PsA 1 and 2 Phase 3 Trials. https://doi.org/10.1007/s40744- ...

Targeting IL-23 for axial disease in PsA - Nature

Post-hoc analysis of data from the phase III DISCOVER-1 and DISCOVER-2 trials suggests that guselkumab, which targets the p19 subunit of IL ...

post-hoc analyses of VOYAGE 1 and 2 - psoriasis-hub.com

Here, we present a visual abstract summarizing post-hoc analyses of the VOYAGE 1 and 2 trials assessing the efficacy of guselkumab in the ...

Efficacy of risankizumab across subgroups in patients with active ...

... psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials.

Plaque Psoriasis (PsA) Efficacy | Enbrel® (etanercept)

A post hoc analysis was conducted for an OLE, including 473 patients from the Global Psoriasis Pivotal Trial after completing a minimum of 36 weeks of open- ...

Efficacy of guselkumab on axial involvement in patients with active ...

... psoriatic arthritis in the phase 3 DISCOVER-1 and DISCOVER-2 studies. We ... These post-hoc analyses of DISCOVER-1 and DISCOVER-2 focused on the effect ...

Disease Control with Upadacitinib in Patients with Psoriatic Arthritis

Methods: This was a post hoc analysis of the double-blind, placebo-controlled SELECT-PsA 1 (also adalimumab-controlled) and SELECT-PsA 2 trials. Treatment ...